JPRN-UMIN000025451已完成未知
Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease - Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 3
研究概览
简要总结
The duration of infliximab for the 3 cases was an average of 7 years and 8 months, and the remission of ocular inflammation after introduction of infliximab was an average of 6 years and 8 months. In all cases, there was no eye inflammation attack for 1 year, the eye activity score remained at 0, and there were no cases of reintroduction of infliximab. However, all cases had relapsed systemic symptoms such as extraocular symptoms such as folliculitis,recurrent oral aphthae, and unknown fever.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients with kidney dysfunction 2. Patients with liver dysfunction 3. Patients with pancreatic dysfunction 4. Hypertension patients 5. Patients with infection 6. Patients with malignant tumors (such as malignant lymphoma) or a previous medical history 7. Patients during ultraviolet radiation therapy including PUVA therapy 8. Elderly (65 years and over) 9. Hepatitis B virus carrier, patient with hepatitis C virus carrier 10. Patients who are using contraindicated drugs in combination with cyclosporine,Living vaccine (dry live attenuated measles vaccine, dry live attenuated feline vaccine, oral raw polio vaccine, dry raw BCG, etc.), tacrolimus excluding external medicine (prograf), pitavastatin ), Rosuvastatin (crestor), bosentan (trakuria), aliskiren (radiolith), asnaprevir (sunbella), baniprevir (bani hep) 11. Other patients judged inappropriate by the research doctor
研究者
相似试验
已完成
不适用
Long-term Scheduled Therapy With Infliximab in Inflammatory Bowel DiseaseUlcerative ColitisCrohn's DiseaseNCT02057016Catholic University of the Sacred Heart258
已完成
4 期
Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete RemissionCrohn DiseaseNCT01817426Copenhagen University Hospital at Herlev115
已完成
不适用
One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort StudyArthritis, RheumatoidSpondylitis, AnkylosingArthritis, PsoriaticColitis, UlcerativeCrohn's DiseaseNCT03662919Biogen2,274
Unknown
3 期
The Effect of a Probiotic Preparation (VSL#3) Plus Infliximab in Children With Crohn's DiseaseCrohn's DiseaseNCT01548014Samsung Medical Center1
进行中（未招募）
1 期
A Comparative Study Of A 6-Month Infliximab (Remicade) Or Placebo Regimen In Undifferentiated Arthritis At High Risk For The Development Of Rheumatoid Arthritis : Clinical, Radiological (MRI) And Synovial Benefit P1200/001. - INFLIXIMAB (REMICADE) in UAPatient with undifferentiated arthritis and the presence of anti-CCP antibodies are at high risk to develop RAMedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2007-004694-26-BESaint-Luc Universitary Hospital30